top of page


Recent Posts

Commentaires sur le Règlement sur les médicaments brevetés modifié

(en anglais)

As leaders of organizations in the bio-medical research fields, we are deeply concerned by the recent trends Canada is experiencing both in levels and the availability of funding for medical research activity. We are of the opinion that the detrimental impact of the proposed changes to the PMPRB regulations on the R&D ecosystem have not been adequately considered and that Canadian bio-medical research institutes, clinician-scientists, researchers and Canadian patients will be increasingly adversely impacted through the indirect downstream effects of the proposed changes on research funding in Canada.

June 2020 submission_Exactis Innovation_
Download • 503KB

bottom of page